Clinical Trial Update: Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early to Moderate Stage Multiple System Atrophy (MSA) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the investigational allogeneic cell therapy product hOMSC300 for early to moderate stage Multiple System Atrophy (MSA); the trial statu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple System Atrophy

Drugs mentioned

• hOMSC300

Snippet

Sponsor: Cytora Ltd. | Conditions: Multiple System Atrophy, MSA - Multiple System Atrophy | Phase 1 | Status: ACTIVE_NOT_RECRUITING